PCI BIOTECH ASA NK 3
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more
PCI BIOTECH ASA NK 3 (4QG) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PCI BIOTECH ASA NK 3 (4QG) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PCI BIOTECH ASA NK 3 - Net Assets Trend (None–None)
This chart illustrates how PCI BIOTECH ASA NK 3's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PCI BIOTECH ASA NK 3 (None–None)
The table below shows the annual net assets of PCI BIOTECH ASA NK 3 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PCI BIOTECH ASA NK 3's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PCI BIOTECH ASA NK 3 Competitors by Market Cap
The table below lists competitors of PCI BIOTECH ASA NK 3 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALLIANCES DEVELOPPEMENT IMMOBILIER
BC:ALLIANCES
|
$368.79K |
|
Noble Metal Group Incorporated
V:NMG-H
|
$368.88K |
|
Formuepleje Limittellus
CO:FPILIM
|
$368.96K |
|
FLG-P-U
NYSE:FLG-P-U
|
$369.01K |
|
Regenerative Medical Technology Group Inc.
PINK:RMTG
|
$368.49K |
|
RANGE RESOURCES - Dusseldorf Stock Exchang
DU:RAX
|
$368.39K |
|
ISHS MSCI GER
BE:ISVP
|
$368.20K |
|
FLUOR (FLU.SG)
STU:FLU
|
$368.20K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PCI BIOTECH ASA NK 3's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PCI BIOTECH ASA NK 3's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PCI BIOTECH ASA NK 3 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PCI BIOTECH ASA NK 3's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PCI BIOTECH ASA NK 3 (4QG) | €- | N/A | N/A | $368.58K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |